From 09ce8bb479f02047f09a64d15d1a47d1630af196 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 8 May 2026 04:14:59 +0000 Subject: [PATCH] auto-fix: strip 1 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...26-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md b/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md index 253a7b092..dba808af0 100644 --- a/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md +++ b/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md @@ -66,6 +66,6 @@ intake_tier: research-task **Context:** Cocaine use disorder is the highest-unmet-need SUD category. Two Phase 2 trials recruiting as of early 2025. No completed results. This archive serves as a tracking record for the extractor to know: don't extract efficacy claims yet, revisit when trial results publish. ## Curator Notes (structured handoff for extractor) -PRIMARY CONNECTION: [[GLP-1 receptor agonists reduce substance use disorder risk by 40-75%]] (if this claim exists or is proposed from Session 39 sources) +PRIMARY CONNECTION: GLP-1 receptor agonists reduce substance use disorder risk by 40-75% (if this claim exists or is proposed from Session 39 sources) WHY ARCHIVED: Tracking the CUD trial status so future Vida sessions know exactly where the evidence stands — no completed RCT, two Phase 2 recruiting, check back 2027. EXTRACTION HINT: Do NOT extract efficacy claims. Extract only: (1) the status fact that no pharmacotherapy exists for CUD and (2) the trial pipeline status. The All of Us OR=0.25 should be cited as the observational basis, with confidence flagged as experimental pending RCT.